Big Trial...Chemicals...Modular Building...Jim Cramer
. . . Big trial coming. Patient enrollment has been completed for a pivotal trial evaluating panitumumab as monotherapy for metastatic colorectal cancer patients who have failed standard chemo therapy. Panitumumab, co-developed by Abgenix (Nasdaq: ABGX) and Amgen is an investigational product in a new class of targeted cancer treatments called epidermal growth factor receptor (EGFr) inhibitors. Although EGFr normally helps regulate the growth of many different cells in the body, EGFr can also stimulate cancer cells to grow. Panitumumab binds to EGFr, preventing EGF and TGF alpha from binding to the receptor and interfering with the signals that would otherwise stimulate growth of the cancer cell and allow it to survive.
. . . Versar (Amex: VSR) integrates a wide variety of skills, including chemical and biological expertise, engineering and architectural design, construction, and environmental skills to support America's chemical and biological defense. Recently, it was awarded an engineering services contract from the U.S. Army Edgewood Chemical/Biological Center. The contract is for a five-year term with a ceiling of $100 million.
. . . Closing in on 100%. Global Diversified Industries (GDVI.OB), focused on the modular building industry with an emphasis on the education market, reported revenues for the nine months ended January 31, 2005 were up 99.8% compared to revenues for the previous nine months. It also marked the company's third consecutive quarter of positive earnings. Modular construction, particularly big in the building of education properties, offers advantages of speed and consistent quality.
. . . The Cramer Effect. Jim Cramer started off his new CNBC show Mad Money by lighting a fire under CMGI (Nasdaq:CMGI). He praised the new direction of the company he, like many others, has reviled since the days of the Internet stock bust. Sure enough, the next day share price went from 1.80 to 2.25. It has since gone down a bit, but remains above its price before Cramer's show. The praise was based on the fact that CMGI posted positive operating income for the second consecutive quarter, and the company is now in the very real business of supply chain management as opposed to its previous "Internet incubator" model.
(From www.SmallcapRecap.com)
. . . Versar (Amex: VSR) integrates a wide variety of skills, including chemical and biological expertise, engineering and architectural design, construction, and environmental skills to support America's chemical and biological defense. Recently, it was awarded an engineering services contract from the U.S. Army Edgewood Chemical/Biological Center. The contract is for a five-year term with a ceiling of $100 million.
. . . Closing in on 100%. Global Diversified Industries (GDVI.OB), focused on the modular building industry with an emphasis on the education market, reported revenues for the nine months ended January 31, 2005 were up 99.8% compared to revenues for the previous nine months. It also marked the company's third consecutive quarter of positive earnings. Modular construction, particularly big in the building of education properties, offers advantages of speed and consistent quality.
. . . The Cramer Effect. Jim Cramer started off his new CNBC show Mad Money by lighting a fire under CMGI (Nasdaq:CMGI). He praised the new direction of the company he, like many others, has reviled since the days of the Internet stock bust. Sure enough, the next day share price went from 1.80 to 2.25. It has since gone down a bit, but remains above its price before Cramer's show. The praise was based on the fact that CMGI posted positive operating income for the second consecutive quarter, and the company is now in the very real business of supply chain management as opposed to its previous "Internet incubator" model.
(From www.SmallcapRecap.com)
posted by laltman at 9:07 AM
0 Comments:
Post a Comment
<< Home